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Representation of authors and editors from poor countries
Observed publication bias may reflect
who is funding research
Editor—Despite research in tropical medi-
cine being undertaken in countries from low
human development index, authorship and
editorial opinion remain with countries
from higher development index. This unfair
trend observed by Keiser et al demands to
be addressed and overturned.1
This observed bias may arise because
countries of high human development
index fund the bulk of research in tropical
medicine.2 3 Authors from these countries
have prepared the grant applications, taken
principal investigator status, and believe that
they should take primary or terminal
authorship. Researchers from low human
development index countries can break this
cycle only if they can obtain international
funding themselves or are allowed author-
ship by the principal investigators. It seems
this is rarely extended to the collaborators in
tropical countries, even though they are the
ones practically conducting the study.
If such generosity in authorship and
mentorship were provided, this would
enable researchers from low human devel-
opment index countries to become success-
ful principal investigators, obtain funding,
and be invited to the editorial board of
respected journals. Keiser et al could have
examined the funding source of the
published research articles against author-
ship country of origin to see if this was
confounding.
We are sure that these publication biases
are not just restricted to tropical medicine.
Consequently, we strongly advocate this
approach be delivered uniformly across all
clinical disciplines to support research and
researchers in countries of low human
development index, who are concurrently
tackling substantial healthcare inequalities
and unremitting disease,4 and deservedly
need greater support.
Ranjit Manchanda specialist registrar obstetrics and
gynaecology
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Rajesh Varma MRC fellow in obstetrics and
gynaecology
Academic Department of Obstetrics and
Gynaecology, Birmingham Women’s Hospital,
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Partnerships may well be unequal
Editor—The findings by Keiser et al with
regard to poor representation of countries
with a low human development index on the
boards of international journals in tropical
medicine is not surprising.1 They have done
well to highlight this disparity in an area
where local knowledge is key. It would also be
interesting to examine whether there was
notable overlap between different boards. In
other words, did the developing country
members consist of “the usual suspects”?
Underinvestment in research and health
care in many developing countries undoubt-
edly accounts for some of the disparity. Yet
the issues of wider power dynamics play a
part. For example, the authors call for more
research partnership between richer and
poorer nations, but the question is whether
you can have a partnership of unequals.
With most of the funding for research com-
ing from the wealthier countries of the West,
it is extremely difficult, and perhaps
impossible, for the research agenda not to
be dictated by them and for the richest of the
“fruits” not to go to them. Perhaps the inno-
vative scheme by the Wellcome Trust to help
establish researchers in tropical medicine
from developing countries and to support
their careers may improve the situation.
Similarly, the existence of African Jour-
nals On Line (supported by the Interna-
tional Network of the Availability of Science
Publications) and other such initiatives may
help foster relationships between research-
ers in different countries. That said,
improved public and private sector funding
of research from within developing coun-
tries must also be encouraged.
Ike Anya specialist registrar in public health medicine
Bristol North Primary Care Trust, Bristol BS2 8EE
ikechuku.anya@lshtm.ac.uk
Competing interests: IA is a citizen of Nigeria.
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Quality medical research from poor
countries could be privileged in high
impact journals
Editor—Keiser et al highlight the obvious
under-representation of authors and edi-
tors from countries with low human
development indexes in prestigious tropical
medicine journals.1 This shows the paradox
of the greater burden of tropical disease
afflicting people living in the underdevel-
oped world being studied, then published,
by researchers in countries with a high
development index.
Great obstacles confront researchers
who live and work in countries that are poor
in resources, and where diseases are
prevalent, in conducting and publishing
medical research into diseases of poverty.2
These inequities are exacerbated by poor
dissemination of and reduced access to
quality medical research among clinicians in
countries where these diseases are endemic.3
This may be ameliorated by allowing
duplicate publication in local journals or
forums of difficult to access articles from
prestigious journals with high local rel-
evance, for a lesser cost or for free.4 Journal
space in high impact journals could be
quarantined for articles on locally relevant
medical research conducted by researchers
from less developed countries. Publications
could be actively solicited or commissioned
from researchers who live and work in such
countries in special focus issues.
Although quality clinical research flow
from countries rich in research to countries
poor in research is limited,5 the reverse also
occurs. Awareness of health issues pertain-
ing to less developed countries among
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clinicians in the developed world could be
improved by increased presence of article
summaries and links to publications of note
originating from less developed countries
within sections such as Journal Watch.
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Raised cardiac troponins
Troponins seem to be sensitive but not
specific
Editor—The initial statement in Ammann
et al’s editorial on raised cardiac troponins,
“Troponin T and troponin I are highly
sensitive and specific markers of myocardial
injury,” is contradicted by a later statement:
“In sepsis, for example, cardiac troponins
are raised in up to 85% of patients in the
absence of any acute coronary syndromes.”1
Although troponins are clearly highly
sensitive for acute coronary syndromes, and
therefore valuable for risk stratification in
patients presenting with classic cardiac chest
pain, the real issue is the specificity of
troponin assays when randomly applied in
general medical admissions units to patients
presenting as unwell (and not necessarily
with cardiac syndromes). Given a high false
positive rate in non-cardiac conditions—
sepsis syndromes, eclampsia, and others—
their specificity must be suspect.
Not unusually, an admitting junior doctor
merrily “ticks all the boxes” on the clinical
chemistry form and the patient (who clearly
has pneumonia, without cardiac chest pain,
and with a pristine electrocardiogram) has a
raised troponin T concentration. Although
this result does not necessarily imply a
coexistent (clinically unsuspected) acute coro-
nary syndrome, it does have prognostic
implications for the pneumonia.
For my personal “missing from the list of
diseases associated with raised troponins”
diagnosis, I offer dermatomyositis.
Matthew L Grove consultant rheumatologist
Tyneside General Hospital, North Shields
NE29 8NH
Matthew.Grove@northumbria-healthcare.nhs.uk
Competing interests: None declared.
1 Ammann P, Pfisterer M, Fehr T, Rickli H. Raised cardiac
troponins. BMJ 2004;328:1028-9. (1 May.)
Troponin is raised in pre-eclampsia
Editor—In their editorial on raised cardiac
troponins Ammann et al omit an important
cause of increased troponin concentration
in obstetric medicine—gestational hyperten-
sion and pre-eclampsia.1
Fleming et al showed fivefold higher
median values for cardiac troponin I in pre-
eclamptic women than in normotensive
pregnant women.2 These median values
were above those which would be indicative
of significant myocardial damage. Aware-
ness of this becomes important in women
with severe pre-eclampsia complicated by
pulmonary oedema, the pathogenesis of
which is likely to be multifactorial related to
capillary leak, hypoalbuminaemia, hyperten-
sion, and global left ventricular dysfunction.
It is also important as the other commonly
used marker of myocardial ischaemia, the
MB isoenzyme of creatine kinase, is raised in
around a third of normal pregnant women
on the first postpartum day after vaginal
delivery.3
Adam Morton endocrinologist and obstetric physician
Mater Hospital, South Brisbane, QLD 4101,
Australia
amorton@mater.org.au
Competing interests: None declared.
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Brief lifestyle interventions for
hypertension
Opportunity to provide useful
information has been missed
Editor—Little et al address an important
topic in their trial of dietary advice for
patients with a single high blood pressure
reading in primary care.1
Robust evidence from ran-
domised controlled trials
of the effectiveness of
nurse led hypertension
management in primary
care is lacking.2 No men-
tion is made of a possible
cluster effect of different
practices, neither do the
authors clarify whether
randomisation was bal-
anced within practices. Neither nurses
assessing outcomes nor patients were
blinded to the intervention arm.
The entry assessment of blood pressure
does not follow guidelines from the British
Hypertension Society (neither does that at six
months), which indicates that at least two
measurements (1-2 minutes apart) should be
taken on each occasion.3 The patients
enrolled would probably have had normal
blood pressure and therefore would have
been less likely to respond to treatment, since
the blood pressure response to any treatment
is greater the higher the blood pressure.
A reduction of sodium intake to
< 100 mmol/day (or to < 6 g salt) would be
expected to reduce systolic blood pressure
by 2-8 mm Hg.3 Low sodium salt achieved a
reduction in sodium to potassium ratio of
0.32 (95% confidence interval 0.08 to 0.56).
This is comparable to the changes seen
in older patients with a higher blood
pressure.4 Nevertheless, a 1.3 mm Hg lower
systolic blood pressure at one month and
1.4 mm Hg at six months is observed,
although this does not reach significance.
This is exactly the effect on blood
pressure to be expected from that change in
the ratio of sodium to potassium in younger
people with normal blood pressure.5 The
study was probably underpowered to detect
such a difference. The modest rise in the
anxiety score at one month (not sustained at
six months) with low sodium salt is difficult
to interpret since the trial was not double
blind.
The outcome of this trial could have
been predicted by a scrupulous examination
of the study design. An opportunity to
provide useful information has been missed.
Francesco P Cappuccio professor of clinical
epidemiology and primary care
Department of Community Health Sciences,
St George’s Hospital Medical School, London
SW17 0RE
sghq200@sghms.ac.uk
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Authors’ reply
Editor—Cappuccio’s sugges-
tions do not explain the results.
Nurses measured blood
pressure by using semi-
automated monitors (minimis-
ing measurement bias) and
gave structured advice in all groups (mini-
mising placebo effect1 2). Any bias is likely to
favour the active interventions, and there
was no evidence of this.
General practitioners and nurses were
asked to refer patients after two to three
readings, using appropriate cuff sizes on a
single occasion—the group targeted for
non-pharmacological advice according to
guidelines from the British Hypertension
Society. After a few weeks the baseline blood
pressure (the mean of three readings on the
second occasion) was 153/93 mm Hg, simi-
lar to the previous smaller Dutch study
(158/91 mm Hg), which indicated that low
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sodium salt was effective.3 When patients
with a baseline diastolic blood pressure
above 90 mm Hg (n = 171) were selected
the estimate for the low salt group was
− 1.16 mm Hg (95% confidence interval
− 3.5 to 1.18). When patients older than 60
(n = 94—a similar power to the Dutch study)
were selected the estimate was 0.001 mmHg
( − 3.17 to 3.17).
Robust standard errors, allowing for clus-
tering, were almost identical (slightly
lower)—as expected with individual randomi-
sation and a highly structured approach.
There are two likely reasons for the lack
of effect: low sodium salt is not very effective,
and in a pragmatic trial the control group
are not constrained to a constant diet and
know that they aren’t getting low salt—and
thus may be more motivated to change diet
in response to basic advice (as we observed).
Hence even among elderly patients and
those with more definite hypertension the
effect may be less than expected. To balance
blinded “efficacy” trials we also need
evidence from pragmatic open trials
designed to look at the effect of advice in
everyday practice—where patients’ behav-
iour is rather more realistic.
Paul Little professor of primary care research
P.Little@soton.ac.uk
Jo Kelly research assistant
Jane Barnett research nurse
Martina Dorward research nurse
University of Southampton, Division of Community
Clinical Sciences, Primary Medical Care Group,
Southampton SO16 5ST
Barrie Margetts senior lecturer in public health
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Daniel Warm lecturer in public health nutrition
Public Health Nutrition, University of
Southampton, Community Clinical Sciences
Division, Southampton General Hospital,
Southampton SO16 6YD
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Treatment of hepatic
encephalopathy
It’s not lactulose
Editor—Als-Nielsen et al systematically
reviewed randomised trials using lactulose
or lactilol for hepatic encephalopathy,1
which has been warranted for some time.
We agree that non-absorbable disaccharides
have been introduced into clinical practice
without any convincing evidence base but
question the authors’ conclusion, that there
is insufficient evidence to determine
whether non-absorbable disaccharides are
of benefit to patients with hepatic encepha-
lopathy. Surely, this comprehensive review
shows clearly that lactulose is ineffective for
treatment of hepatic encephalopathy, rather
than there being insufficient evidence.
Furthermore, the results of this study
have several important implications.
Firstly, what should comprise standard
medical treatment for hepatic encephalopa-
thy? Lactulose should no longer be included,
but strict attention should be paid to treating
the precipitating factors, with correction of
dehydration, electrolyte and acid base imbal-
ance,2 constipation, and infection.3
Secondly, we make a plea for placebo
controlled trials: no restriction should be
imposed on the conduct of placebo control-
led studies on ethical grounds.
Thirdly, the interorgan metabolism of
ammonia should be revisited and the recent
studies showing the important roles of the
small intestine, muscle, and kidneys in regu-
lating the blood concentrations of ammonia
considered.4
Debbie L Shawcross research fellow
d.shawcross@ucl.ac.uk
Rajiv Jalan senior lecturer
Liver Failure Group, Institute of Hepatology,
London WC1E 6HX
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Authors’ reply
Editor—We do not agree that our
Cochrane review clearly shows that lactulose
is ineffective. The fact that we found no evi-
dence of effect does not imply that there is
evidence of no effect.1 It is difficult to prove
that a treatment has no effect.1
A survey of 989 abstracts of Cochrane
reviews showed that inappropriate claims of
no effect were made in 240 (22.5%)
abstracts.2 In our review, we found that high
quality trials found no significant effect of
lactulose on the risk of no improvement of
hepatic encephalopathy (relative risk 0.92,
95% confidence interval 0.42 to 2.04). The
confidence interval indicates that we cannot
exclude that lactulose may benefit (reduce
the risk of no improvement by up to 58%).
On the other hand, lactulose may also harm
(increase the risk of no improvement by up
to 104%). Our meta-analysis is based on
only two trials with a total of 46 patients.
Accordingly, our analysis has low power to
detect clinically beneficial or harmful effect.
A consequence of claiming no effect
would be that further research assessing the
effect of lactulose is unnecessary.We find that
a large, randomised, parallel, double blind
trial is warranted. It would be interesting to
compare lactulose, another laxative (magne-
sium or sorbitol) prepared to appear and
taste like non-absorbable disaccharides, and a
placebo of similar taste and appearance but
without a cathartic effect (such as glucose).
We agree that lactulose should not be
part of standard treatment of hepatic
encephalopathy, and that placebo controlled
trials are mandatory in this field, where none
of the current treatments has proved
clinically effective.
Bodil Als-Nielsen research fellow
Bodil.a@ctu.rh.dk
Lise L Gluud research fellow
Christian Gluud chief physician
Cochrane Hepato-Biliary Group, Copenhagen
Trial Unit, Centre for Clinical Intervention
Research, Copenhagen University Hospital,
Department 7102, H:S Rigshospitalet, DK-2100
Copenhagen, Denmark
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Patient organisations in ME
and CFS seek only
understanding
Editor—To compare general practitioners’
attitudes to patients with chronic fatigue
syndrome (CFS) or myalgic encephalomy-
elitis (ME) and those with irritable bowel
syndrome was disappointing in the study by
Raine et al.1 Particularly disappointing was
that the study was conducted in the months
after the chief medical officer recognised—
with considerable attendant publicity—the
severity and impact of chronic fatigue
syndrome or myalgic encephalomyelitis on
the lives of those affected.2
One outcome of the study was that pres-
sure groups were perceived as influencing
clinical encounters, making it harder to
legitimise the symptoms. That the authors
labelled patients’ organisations “pressure
groups” was interesting in itself.
The organisations cover a range of views
on the illness and the solutions needed. This
organisation carries out an information role
for patients and professionals and provides a
range of services no different from that of any
other medium sized charity (www.afme.
org.uk). We campaign vigorously of course
for recognition of chronic fatigue syndrome
and myalgic encephalomyelitis and for fund-
ing to remedy years of neglect in this field.
We are not “antidoctor” and our
members mostly view their general practi-
tioners as supportive and understanding but
faced with a complex illness and lacking a
toolkit to help.
Far from patients’ organisations wishing
to politicise the consulting room, we simply
ask for a little more understanding, mixed
with a little humility and matched with an
eagerness to obtain training and informa-
tion about diagnosis and treatment.
We do not seek a special status, just that
people who are ill with chronic fatigue
syndrome or myalgic encephalomyelitis
should be treated with the standard of care
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and professionalism that the severity and
impact of their illness merits. Is this politics?
Chris Clark chief executive
Action for ME, London EC1M 9BL
chris@afme.org.uk
Competing interests: CC is chief executive,
Action for ME.
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Should reviewers of papers
have their names published?
Reviewing is not vicarious authorship
Editor—Dimoliatis raises some important
points in his personal view asking whether
reviewers of papers should have their names
published.1 There are two aspects of the
debate on open access reviewing that strike
me as interesting points from a qualitative
perspective. The first is whether the authors
think that the paper has been genuinely
improved and the second whether readers
preferred the first or second version.
Firstly, speaking as an author, I know
many hurt feelings may result from seeing a
beloved creation “grow up” in a completely
unexpected way. Although there can be the
benefits of a more coherent and rigorous
paper that is more scientifically readable,
there can be the risk of “watering down” the
message with rather soulless, lifeless papers
as the end result.
Secondly, from a reviewer perspective,
there is no way I could condone “hijacking”
authorship, no matter how much work has
gone into reviewing. We are privileged to be
exposed to new ideas and different ways of
viewing things; we are simply there to clarify,
simplify, and amplify points—and not as
vicarious authors. This is a fine line—but
remember, who came up with the idea for
the paper in the first place?
Reviewers should also be reviewed on
the quality of what they do and this should
be open—what have we got to hide? Perhaps
reviewers should also be asked to explain
their decisions more and why they think the
paper grew and flourished as a result of
their intervention.
Sean P J Lynch honorary senior clinical research
fellow
Mental Health Research Group, Peninsula Medical
School, Wonford House Hospital, Exeter EX2 5AF
SeanLynch2@yahoo.co.uk
Competing interests: SL is editor of Primary Care
Psychiatry. The views expressed are his own and
not necessarily those of the journal.
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Let reviewers own responsibility for the
papers they pass
Editor—The article by Dimoliatis on
whether reviewers should have their names
published and the electronic responses to it
discussed an interesting issue.1 2 We worked
as student editors for our college magazine,
which is but a small thing when considering
the context of the current discussion. But we
know how tiring the work seemed some-
times as we had to read every single article,
understand the logic, and go to the depths
before we could reject any article. It seemed
as if sometimes we worked harder than the
authors themselves.
As most of the journals follow a double
blinded policy for review, we do not see any
reason why a reviewer’s name should not be
included at the end. We agree that being a
reviewer of a journal is an achievement in
itself, but we could give more credit to review-
ers for doing, what they sometimes might
perceive as, a thankless job. To the question
that more substandard articles would get
published—well, we cannot police everything
and everyone. Reviewers are persons of
repute and holding high positions them-
selves. We are sure most would still be honest
about their job and not just pass a paper
because their name is published with it. On
the contrary, their name is at stake if a
substandard article passes through. This
might actually make them work harder
towards the standard and the value of the
article they pass, and that they in a way
guarantee.
Sashidhar V Yeluri senior resident in general surgery
y.sashidhar@mailcity.com
Amit Kapoor senior resident in orthopaedics
Guneesh Dadayal house officer in surgery
Jayshree Panwar house officer in surgery
Department of Surgery, Sir Sayajirao General
Hospital and Medical College, Indira Avenue Road,
Baroda-390001, India
Competing interests: SVY has recently joined
the editorial board of the Asian Students Medical
Journal as an associate student editor.
1 Dimoliatis I. Should reviewers of papers have their names
published? BMJ 2004;328:1267. (22 May.)
2 Electronic responses. Should reviewers of papers have
their names published? bmj.bmjjournals.com 2004.
bmj.bmjjournals.com/cgi/eletters/328/7450/1267
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Practical example gives encouraging
insights
Editor—The Journal of Medical Internet
Research (www.jmir.org), an open access
journal that I edit, has for five years practised
routinely what Dimoliatis proposes1: review-
ers are acknowledged at the end of each
published article.
In our experience, concerns over review-
ers becoming too uncritical only to see their
name published are unfounded. Moreover,
editors never follow blindly the recommen-
dation of the reviewer(s). It is comparatively
easy to identify review reports that are too
uncritical or superficial. Reviewers’ com-
ments are intended mainly as an opportu-
nity for authors to improve their manu-
script. Few editors will admit this, but if
editors really want to see something
published, they will overrule the overly criti-
cal reviewers, and vice versa.
Herein lays the real (and only) problem
of publishing reviewers’ names, which we
encounter from time to time. If one reviewer
strongly thinks that a paper should not be
published, but the second reviewer or editor
overrules the recommendation of one
reviewer, the reviewer may not be happy to
see his or her name published at the end of
a paper. We did have reviewers objecting to
publish their name at the end of an article if
we accepted it.
The appropriate solution to this is to
educate readers that publishing reviewers’
names is a mere acknowledgment of their
work and the input they gave, and that it is
not necessarily an endorsement of a
manuscript. If this can be accepted, acknowl-
edging reviewers at the end of articles will
and should become common practice in
other journals.
Gunther Eysenbach senior scientist
Centre for Global eHealth Innovation, Division of
Medical Decision Making and Health Care
Research, Toronto General Research Institute of
the UHN, Toronto General Hospital, R. Fraser
Elliott Building, 4th Floor, room [ 4S435, 190
Elizabeth Street, Toronto, ON, Canada M5G 2C4
geysenba@uhnres.utoronto.ca
Competing interests: GE is editor in chief of the
Journal of Medical Internet Research, a non-profit
open access journal on ehealth.
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Go one step further
Editor—Dimoliatis’s cri de coeur for better
recognition of reviewers of papers has much
merit.1 Some of your respondents,2 however,
are concerned that the quality of peer review
could suffer as reviewers succumb to the
temptation of seeing their names in print;
the counter argument so cogently put forth
by Yeluri et al (letter in this cluster) is a
forceful one: reviewers’ reputations are at
stake if a substandard article passes through.
Although most journals do not publicly
acknowledge the efforts of their reviewers,
which are so essential to the credibility (and
quality) of the published work, some appease
their reviewers by publishing their names
periodically. Several open access publishers,
as other respondents have pointed out,
publish full details of the review process
alongside the published paper.2
I dare publishers to go one step further:
publish a list of all papers received and
rejected at peer review, with the names of the
reviewers. This would ensure the highest
quality of peer-review, greater transparency,
and a sense of justice for authors of rejected
papers. I would then be interested to see if
such papers eventually find a home, and in
what form.
Akheel A Syed specialist registrar
University of Newcastle, Newcastle upon Tyne,
NE2 4HH
a.a.syed@ncl.ac.uk
Competing interests: AAS may live to regret his
dare.
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